| Not Yet Recruiting | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Mon NCT07482657 | Enanta Pharmaceuticals, Inc | Phase 2 |
| Not Yet Recruiting | TARSILA Real-World Evidence Study NCT07445763 | Inova Medical | — |
| Not Yet Recruiting | Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Parti NCT07516418 | Sanofi | Phase 1 |
| Not Yet Recruiting | Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in He NCT07492706 | MAXVAX Biotechnology Limited Liability Company | Phase 1 |
| Not Yet Recruiting | Phase Ib/IIa Clinical Trial of SIBP-A16 Injection in Premature Infants and Full-term Infants NCT07363837 | Shanghai Institute Of Biological Products | Phase 1 / Phase 2 |
| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Recruiting | Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease NCT06851806 | AstraZeneca | N/A |
| Recruiting | Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons NCT07050732 | Johns Hopkins University | Phase 2 |
| Active Not Recruiting | Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants NCT07249320 | Pfizer | — |
| Recruiting | Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) NCT07272434 | MAXVAX Biotechnology Limited Liability Company | Phase 3 |
| Active Not Recruiting | Systems Biological Analysis of Immune Responses to RSV Vaccine NCT07185399 | Emory University | Phase 4 |
| Recruiting | A Clinical Trial of SIBP-A16 Injection in Healthy Adults NCT07106918 | Shanghai Institute Of Biological Products | EARLY_Phase 1 |
| Active Not Recruiting | STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus NCT07122661 | Pfizer | — |
| Recruiting | Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV NCT06873633 | PENTA Foundation | Phase 2 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adul NCT06890416 | Pfizer | Phase 3 |
| Active Not Recruiting | Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above NCT06642558 | MAXVAX Biotechnology Limited Liability Company | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV NCT06564194 | Immorna Biotherapeutics, Inc. | Phase 1 |
| Active Not Recruiting | A Safety and Immunogenicity Trial of a Respiratory Syncytial Virus Vaccine, LYB005 in Healthy Adults NCT06442241 | Guangzhou Patronus Biotech Co., Ltd. | Phase 1 |
| Recruiting | Peginterferon α-2b Injection for Aerosol Therapy in Pediatric Respiratory Syncytial Virus Pneumonia NCT06881056 | West China Second University Hospital | N/A |
| Recruiting | RSV Vaccine Pregnancy Registry NCT06521944 | CorEvitas | — |
| Completed | A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Ad NCT06473519 | Pfizer | Phase 3 |
| Active Not Recruiting | Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Y NCT06216093 | EuBiologics Co.,Ltd | Phase 1 |
| Not Yet Recruiting | LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in S NCT06392451 | DiaSorin Molecular LLC | N/A |
| Completed | Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adop NCT06229444 | Evidation Health | N/A |
| Completed | Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Be NCT06207929 | Evidation Health | — |
| Unknown | Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory NCT06175611 | EDAN Instruments Inc. | — |
| Completed | Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF) NCT06077149 | University of Rochester | Phase 4 |
| Completed | Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis NCT06185647 | Hôpital Armand Trousseau | — |
| Active Not Recruiting | Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infection NCT05929599 | National Children's Hospital, Vietnam | N/A |
| Active Not Recruiting | Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study) NCT05913700 | Institute for Clinical Effectiveness, Japan | — |
| Completed | A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age NCT05900154 | Pfizer | Phase 1 |
| Completed | A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV NCT05842967 | Pfizer | Phase 3 |
| Completed | Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV) NCT06067191 | Pfizer | Phase 1 |
| Completed | A Study to Evaluate EDP 938 Regimens in Children With RSV NCT04816721 | Enanta Pharmaceuticals, Inc | Phase 2 |
| Recruiting | Antibiotic Therapy in Viral Airway Infections NCT05045612 | University Hospital, Akershus | Phase 4 |
| Unknown | Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6- NCT04909021 | Meissa Vaccines, Inc. | Phase 1 |
| Completed | Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects NCT04927793 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Active Not Recruiting | Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using NCT04896853 | NextCell Pharma Ab | Phase 1 |
| Unknown | Community-based RSV Surveillance in Infant Mortality: Minimally Invasive Tissue Sampling Study in Karachi, Pak NCT05047549 | Aga Khan University | — |
| Unknown | Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Af NCT05277298 | National Institute for Communicable Diseases, South Africa | — |
| Active Not Recruiting | Transplacental Transmission of RSV (TTRSV) NCT05443607 | Tulane University | — |
| Completed | Effects of Prone Positioning on Vital Parameters in Infants With Acute Bronchiolitis NCT04748159 | Luzerner Kantonsspital | N/A |
| Terminated | A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respirator NCT04225897 | Pfizer | Phase 2 |
| Terminated | Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV NCT03916185 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | High Flow Nasal Cannula Therapy in Bronchiolitis : Early vs Rescue NCT03095495 | Hamad Medical Corporation | N/A |
| Active Not Recruiting | Understanding RSV: Severe Disease and the Long Term Consequences NCT03756766 | University of Oxford | — |
| Completed | A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786 NCT03236233 | Pulmocide Ltd | Phase 1 |
| Unknown | Respiratory Syncytial Virus (RSV) and Vaccination in Pregnancy NCT03096574 | University Hospital Southampton NHS Foundation Trust | — |
| Completed | A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe NCT02968173 | AbbVie | Phase 3 |
| Completed | Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f) NCT02830932 | Vaxart | Phase 1 |
| Completed | Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection NCT02534350 | Gilead Sciences | Phase 2 |
| Completed | A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults NCT02608502 | Novavax | Phase 3 |
| Completed | Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Pla NCT02593071 | Novavax | Phase 2 |
| Completed | A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults NCT02289820 | MedImmune LLC | Phase 1 |
| Completed | A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncyti NCT02298179 | GlaxoSmithKline | Phase 1 |
| Completed | Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Childr NCT02282982 | AbbVie | — |
| Completed | Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults NCT02266628 | Novavax | Phase 2 |
| Completed | A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults NCT02115815 | MedImmune LLC | Phase 1 |
| Completed | Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer NCT02067286 | IQuum, Inc. | — |
| Unknown | Infection With Respiratory Syncytial Virus in Infants NCT04925310 | Hannover Medical School | — |
| Completed | RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly NCT01709019 | Novavax | Phase 1 |
| Completed | RSV-F Vaccine Dose Ranging Study in Young Women NCT01704365 | Novavax | Phase 2 |
| Completed | Burden of Respiratory Syncytial Virus (RSV) in Children in Sweden (BRICS): A Retrospective Study in Sweden NCT05622331 | Sanofi Pasteur, a Sanofi Company | — |